Articles tagged with Drug Discovery
Researchers have discovered toxic DNA buildup in the eyes of patients with geographic atrophy, a devastating form of age-related macular degeneration. Common HIV drugs or safer alternatives, such as Kamuvudines, may block inflammation and protect against retinal cell death, offering new hope for treatment.
A new platform was established for induced pluripotent stem cell research using Maholo LabDroid, demonstrating superior reproducibility and flexibility. The system enabled the cultivation of undifferentiated iPSCs for 63 days and achieved high differentiation rates with minimal variability.
Researchers discovered a combination of two drugs can reduce inflammation following chemotherapy, preventing metastasis in pancreatic and liver cancer. The treatment targets the sEH and EP4 pathways, modulating inflammation to resolve cytokine storms.
Patients with certain gene mutations are at high risk of fatal chemotherapy toxicity, with a 25-times increased risk detected in those with uncommon DPYD variants. The study suggests that adding pre-treatment screening may help prevent avoidable deaths without interrupting standard care.
The Alzheimer's Drug Discovery Foundation has provided NeuroVision Imaging Inc. with additional funding to accelerate the development of a novel blood-based lab test that can predict dementia before clinical onset. This technology has the potential to make diagnostic testing more practical, less invasive and less costly.
Researchers have identified several drug contenders that can block or reduce SARS-CoV2 infection in cells, including lactoferrin and MEK-inhibitors. These findings suggest potential efficacy against COVID-19 variants, with ongoing clinical trials to examine their ability to reduce viral loads and inflammation.
Researchers at Tel Aviv University successfully printed the first entirely active and viable glioblastoma tumor using a 3D printer. The 3D-bioprinted model includes functional blood vessels that simulate a real tumor, making it a promising tool for predicting treatment efficacy and drug development.
Researchers at the University of Huddersfield have developed a new approach to combat cancer treatment challenges by creating self-assembled drugs with high specificity towards human cancer cells. The breakthrough demonstrates unprecedented anti-cancer activity and selectivity in laboratory testing.
Researchers at Berkeley Lab have made significant breakthroughs in developing a highly effective COVID-19 antibody therapy and an efficient thermoelectric system that can convert waste heat to electricity. The new antibody, S309, has been shown to neutralize all known SARS-CoV-2 strains and may be more difficult for new mutants to escape.
A team of chemists developed a new set of modifiable polymers made from SOF4, allowing for environmentally safe reactions and fast production. This breakthrough enables the generation of a vast library of polymers with distinct properties for applications in drug discovery and material science.
Researchers at South Ural State University used computer modeling to identify a substance that can block the spread of coronavirus. The study found that ligands must match RNA polymerase as closely as possible to be effective, and scientists have developed an equation to test other ligands' effectiveness on receptors.
A new process for making RNA has been developed by researchers at the University of Massachusetts Amherst, yielding purer and more abundant RNA at a fraction of the cost. This breakthrough removes the largest stumbling block on the path to next-generation RNA therapeutic drugs.
Scientists at Rockefeller University have discovered that essential gene targets in TB bacteria can be ranked by their degree of vulnerability to antibiotics. The study found that ideal targets are highly susceptible to inhibition, while invulnerable genes can withstand nearly total inhibition. This research provides new insights into ...
A recent study by Queen Mary University of London provides new insight into the mechanisms behind uncontrolled inflammation in COVID-19 patients. The research found that treatments increasing specialised pro-resolving mediators (SPM) production, such as dexamethasone, may play a key role in limiting disease severity.
Researchers at Washington University in St. Louis used comparative metabologenomics to study the genomes of Streptomyces bacteria and identify key factors that influence drug production. The study found that fine-tuning of specific nucleotides can control antibiotic production, offering new insights for next-generation drug discovery.
A phase 2 study found that riluzole slowed brain metabolic decline and improved cognitive performance in patients with mild Alzheimer's disease. The drug targets glutamate dysregulation thought to contribute to the development of Alzheimer's.
A team of scientists has developed an iridium-catalyzed hydrogen addition method to control asymmetry in drug synthesis. This approach reduces wasteful by-products and enables targeted synthesis with high precision.
Researchers at RUDN University have discovered a new three-component reaction that results in the synthesis of acetimidamides, heterocyclic compounds with biological activity. The reaction reaches an efficiency of up to 96% and can be used for the synthesis of hormones, anti-inflammatory drugs, and other medical substances.
Scientists at Tokyo Institute of Technology developed a computational method to predict the cell-membrane permeability of cyclic peptides, exhibiting promising accuracy. The protocol has potential to aid in designing and discovering cyclic peptide drugs with high cell-membrane permeability.
Researchers at University of California San Diego School of Medicine developed a new AI methodology to hunt for disease targets and predict drug success. The approach, which uses machine learning to analyze big data, was tested in a Phase '0' clinical trial and showed high accuracy across diverse IBD patient cohorts.
Researchers from Oak Ridge National Laboratory used Stampede2 to refine the screening of potential drug molecules targeting COVID-19's spike protein. The method, developed by Stephan Irle and Van Quan Vuong, uses quantum mechanics-based ranking refinement and binding analysis to identify top candidates for further testing.
A breakthrough in tracking RNA with fluorescence allows researchers to follow messenger RNA molecules in real time, enabling the development of new RNA-based medicines. This method provides crucial information for optimising drug discovery and understanding how mRNA is taken up into cells.
Scientists from Hackensack Meridian Center for Discovery and Innovation have uncovered the mechanism of action of a novel anti-tuberculosis drug, triaza-coumarin, which is effective in inhibiting TB disease from within by boosting its on-target activity by two orders of magnitude.
Researchers at Northwestern University have identified a novel target for a drug to treat SARS-CoV-2 and potential future coronaviruses. The new therapy could be taken early in the disease to prevent severe symptoms.
The June edition of SLAS Discovery features the cover article on developing high-throughput biochemical assays to assess small molecule impact on SARS-CoV-2 nonstructural protein 14. The issue also includes nine original research articles, covering topics such as HIV latency reversal, kinase inhibitors, and drug combination screening.
Researchers at Carnegie Mellon University have developed a machine learning platform that can identify natural product drugs for treating various ailments. The platform, called NRPminer, uses genomic and metabolomics data to detect promising natural products, including four novel compounds with potential antimalarial properties.
A collaborative research team has discovered compounds with antimalarial activity from a collection of 80,000 drug-like molecules. The most promising candidates are now being further developed towards potential antimalarial drugs.
Researchers at 48Hour Discovery will screen billions of peptides to identify hit compounds for pharmaceutical giant Merck. The two-year project aims to accelerate drug development and address unmet medical needs.
Researchers analyzed online requests from people who use drugs in Russia and found that online platforms provide essential support and services. The study highlights the effectiveness of remote work in reducing harm and increasing help-seeking behavior among individuals with problematic drug use.
DeepBAR, a new machine learning-based technique, quickly calculates binding affinities between drug candidates and their targets, offering a faster and more efficient approach to drug discovery and protein engineering. The approach yields precise calculations nearly 50 times faster than previous methods.
Researchers are harnessing the power of peptides to develop new therapeutics, leveraging vast libraries and animal venom to discover novel leads. Recent studies have shown promising results in pain relief and biopesticides, highlighting the potential for peptides to revolutionize the pharmaceutical landscape.
Researchers found six FDA-approved drugs that can inhibit protein-cutting enzymes essential for SARS-CoV-2 replication. The study's findings have the potential to develop a broad spectrum of antiviral drugs and prevent future pathogenic SARS-CoV strains.
NeuroVision Imaging, Inc. has received an investment from the Alzheimer's Drug Discovery Foundation (ADDF) to develop reliable and affordable biomarker tests for Alzheimer's disease and related dementias. The goal is to improve clinical trials and monitor response to treatments.
The event aims to address current and future challenges in cancer drug development through panel discussions with eminent speakers. Delegates will learn about key areas for innovation and collaboration to improve cancer treatment.
A global research consortium is proposed to collect and share digital speech and language data to detect early signs of Alzheimer's. The consortium aims to create a comprehensive, harmonized repository of samples from diverse cohorts to develop biomarkers that can monitor disease progression.
A new cancer therapy approach combines gemcitabine chemotherapy with celecoxib, an anti-inflammatory medication, to activate the immune system and fight cancer. The combination has shown potential in improving the percentage of patients who respond to immunotherapy drugs.
Researchers discovered that fluorescent proteins behave like miniature antennas, absorbing and emitting light in specific directions. This finding has significant applications in basic biological research and novel drug discovery.
Insilico Medicine introduces Molecular Sets (MOSES), a benchmarking platform for generative chemistry models, enabling easy comparison and evaluation of new models against existing approaches. The platform provides a curated dataset, metrics, and baselines for assessing model performance.
Researchers at UC Riverside developed a simple, inexpensive way to measure drug dissolution that addresses shortcomings of existing methods. The technique uses a vibrating tube sensor to monitor the weight of individual pellets as they dissolve, providing accurate and continuous measurements.
Scientists have discovered how drug-like small molecules can regulate the activity of therapeutically relevant ion channels, providing new avenues for drug discovery. The study reveals how Pico145 binds to TRPC5 channels, preventing them from opening, and highlights the importance of individual amino acid residues in this binding site.
Scientists at the University of Wisconsin-Madison discovered a new antifungal compound, turbinmicin, in the microbiome of a sea squirt from the Florida Keys. Turbinmicin efficiently targets multi-drug resistant strains of deadly fungi without toxic side effects in mice.
A research team is working on developing new tools to guide the discovery and optimization of new antibacterial agents, addressing the growing challenge of antibiotic resistance.
Researchers from Osaka University have developed a technique to visualize small-molecule drugs in cells using gold nanoparticles and surface-enhanced Raman scattering (SERS) microscopy. This approach allows for real-time observation of the dynamics of small molecules inside target cells, providing valuable insights for drug discovery.
Research reveals that tau protein undergoes stepwise chemical modifications over time, correlating with dementia stage in Alzheimer's disease. The discovery suggests that multiple drugs may be necessary to target tau effectively, with early intervention requiring different therapeutics compared to late-stage treatment.
The University of Luxembourg is pioneering the use of machine learning to identify potent drug candidates and accelerate pharmaceutical development. By combining quantum mechanics and large molecular datasets, researchers hope to overcome challenges in chemical discovery and create novel compounds with tailored properties.
A new machine learning model has been developed to help characterize compounds in the development of new drugs. The model uses tandem mass spectrometry and is based on a small amount of positive and negative training data, making it useful for automating characterization of compounds by chemists.
Insilico Medicine will showcase its latest AI advancements in drug discovery and productive longevity at the Leveraging Intelligent Tech for Drug Development Forum. The company's work on AI-generated molecular structures, synthetic biological data, and clinical trial prediction has garnered significant attention and funding.
The Mark Foundation has launched a new funding program for novel cancer therapeutics. Two projects have been selected, focusing on Ewing sarcoma and leukemias, targeting USP7 and CBP/p300 enzymes with highly selective inhibitors.
South Rampart Pharma, a New Orleans life science company, has been awarded a $1.9 million NIH STTR grant to develop a new class of non-opioid medicines for pain relief and fever reduction. The company aims to create a safer treatment option for acute and chronic pain, which affects hundreds of millions of people worldwide.
Researchers have created ultrapotent compounds to treat Clostridioides difficile (C. diff), a leading cause of healthcare-associated infections in the US. The compounds show significant advantages over current antibiotics, including minimum inhibitory concentration values as low as 0.003 μg/mL and improved prevention of recurrence.
Researchers at Gruthan Bioscience aim to develop a new class of cholesterol-lowering drugs for patients with familial hypercholesterolemia, a rare form of high cholesterol. The startup plans to use its novel cell platform to identify and test promising compounds.
Researchers at UNC-Chapel Hill and Stanford solve the high-resolution structure of psychedelic compounds bound to the 5-HT2A serotonin receptor, revealing key insights into their therapeutic potential. The discovery sets the stage for the exploration of more precise compounds with strong therapeutic effects.
Researchers discovered that hollow multishelled structures can realize sequential drug release through unique temporal-spatial order property. This property enables burst, sustained, and stimulus-responsive release stages, providing a long sterility period in bacteria-rich environments.
Researchers studied the binding of general anesthetics and benzodiazepines to the GABAA receptor in the brain. They found that both types of drugs can bind to multiple sites on the receptor, with differences between them. This discovery could lead to the development of new, more selective anesthetics with fewer side effects.
Austrian researchers identified drug-like compounds that could block a key coronavirus protein called PLpro, found in all coronaviruses. These compounds previously developed to fight SARS showed promise in halting the growth of COVID-19 virus (SARS-CoV-2) in laboratory testing.
Researchers at Waseda University have created a novel method to produce alicyclic compounds from commercially available arenes, promising to accelerate drug discovery research. The new method uses a palladium catalyst and malonates as reactants, producing highly functionalized molecules with diverse properties.
Researchers at UC Riverside developed a drug discovery pipeline to identify effective drugs for treating COVID-19. The team used a powerful machine-learning approach to screen millions of chemicals and identified hundreds of promising candidates, including some that are already FDA-approved.
Rice University scientists have won a $1.9 million NIH grant to explore the use of CRISPR-Cas genome editing in natural fungi to discover new drugs that stay ahead of disease resistance. By understanding how fungi synthesize useful compounds, they aim to create novel drug development toolkits.
A new process developed by SFU chemist Robert Britton and his team allows for the creation of new nucleoside analogues in a fraction of the time previously required. This breakthrough has significant implications for treating viral infections and cancer.
Researchers have developed a catalytic system that directly installs the trifluoromethyl group onto arenes using trifluoroacetic acid. The new reaction offers a milder alternative to existing strategies and has been successfully applied to a diverse array of arenes and heteroarenes.